北京风湿跟痛风的区别(济南治疗痛风石的) (今日更新中)

YANGON, May 6 (Xinhua) -- A five-day Myanmar traditional medicine exhibition is underway in Myanmar's former capital of Yangon beginning Thursday, aimed at promoting the development of the country's traditional medicines and disseminating medical knowledge to the public.With over 120 booths, traditional medicine producing companies are displaying their traditional medicine products and producing accessories as well as giving traditional treating service and medical education talks.As the Myanmar traditional medicine is playing a more and more important role in treating diseases in the country, the government urges traditional medicine practitioners to protect and preserve them from depletion and extinction and to ensure their perpetual existence.Myanmar is conducting research on treatment of major diseases -- diabetes, hypertension, malaria, tuberculosis, diarrhea and dysentery through traditional medicine.To do research more effectively and on a wider scale to have the Myanmar traditional medicine standardized, the country holds traditional medicine practitioners conference every year to introduce the country's traditional medicines and its medical practices and the last conference, which was the 11th, took place in Nay Pyi Taw in December 2010.At the same time, the practitioners are also urged to strive for the promotion of the standard of Myanmar traditional medicine to reach international level.

WASHINGTON, May 11 (Xinhua) -- Johns Hopkins University researchers have demonstrated that human liver cells derived from adult cells coaxed into an embryonic state can engraft and begin regenerating liver tissue in mice with chronic liver damage.The work, published Wednesday in the journal Science Translational Medicine, suggests that liver cells derived from so- called "induced-pluripotent stem cells (iPSCs)" could one day be used as an alternative to liver transplant in patients with serious liver diseases, bypassing long waiting lists for organs and concerns about immune system rejection of donated tissue."Our findings provide a foundation for producing functional liver cells for patients who suffer liver diseases and are in need of transplantation," says Yoon-Young Jang, assistant professor of oncology at the Johns Hopkins Kimmel Cancer Center. "iPSC-derived liver cells not only can be generated in large amounts, but also can be tailored to each patient, preventing immune-rejection problems associated with liver transplants from unmatched donors or embryonic stem cells." A microsopic view shows human embryonic stem cells in various stages of differentiation into liver cells in this photo taken at Stanford University and released by the California Institute for Regenerative Medicine, March 9, 2009iPSCs are made from adult cells that have been genetically reprogrammed to revert to an embryonic stem cell-like state, with the ability to transform into different cell types. Human iPSCs can be generated from various tissues, including skin, blood and liver cells.Although the liver can regenerate in the body, end-stage liver failure caused by diseases like cirrhosis and cancers eventually destroy the liver's regenerative ability, Jang says. Currently, the only option for those patients is to receive a liver organ or liver cell transplant, a supply problem given the severe shortage of donor liver tissue for transplantation. In addition, mature liver cells and adult liver stem cells are difficult to isolate or grow in the laboratory, she says. By contrast, iPSCs can be made from a tiny amount of many kinds of tissue; and the embryonic stem- like iPSCs can grow in laboratory cultures indefinitely.For the study, Jang and colleagues generated human iPSCs from a variety of adult human cells, including liver cells, fibroblasts ( connective tissue cells), bone marrow stem cells and skin cells. They found that though the iPSCs overall were molecularly similar to each other and to embryonic stem cells, they retained a distinct molecular "signature" inherited from the cell of origin.

LOS ANGELES, April 2 (Xinhua) -- The United States could soon be faced with an epidemic of Non-Alcoholic Fatty Liver Disease ( NAFLD), one of the major contributing factors of chronic liver disease (CLD), the American Association for the Advancement of Science (AAAS) reported Saturday.If the current rates of obesity and diabetes continue for another two decades, the prevalence of NAFLD in the U.S. is expected to increase by 50 percent in 2030, AAAS said.The prediction is based on pre-existing clinical survey data over a 10 year period (1988-1994, 1999-2004 and 2005-2008), which included 39,500 adults from three survey cycles, according to the AAAS.Over the three cycles, the prevalence of NAFLD doubled from 5. 51 percent to 11 percent respectively. Furthermore, during the first survey cycle (1988-1994) 46.8 percent of all CLD's was related to NAFLD but by 2005-2008 this had increased to 75.1 percent. In addition, the prevalence of obesity and diabetes, the two key risk factors for NAFLD also steadily increased."If the obesity epidemic is anything to go by, the U.S. NAFLD epidemic may have a ripple effect worldwide," said Mark Thursz, Vice Secretary of the European Association for the Study of the Liver. "It is imperative that health systems continue to drive effective educational programs to reinforce awareness among the general public to alert them of the risks of obesity and promote the importance of diet and exercise."Non-alcoholic fatty liver disease is fast becoming one of the top concerns for clinicians due to the obesity epidemic and it's potential to progress to advanced liver disease which significantly impacts on overall liver-related mortality, Thursz said in remarks published by AAAS' website EurekAlert.org.NAFLD, considered as one of the major causes of morbidity and mortality worldwide, is the term used to describe fat build-up in liver cells in people who do not drink alcohol excessively. The disease is the most common persistent liver disorder in Western countries with an estimated overall prevalence of 20-30 percent, according to AAAS.NAFLD encompasses a spectrum of liver disease associated with insulin resistance, diabetes and obesity and as such people most at risk of NAFLD are those who are obese, have insulin resistance associated with diabetes, high blood pressure and cholesterol.

BEIJING, May 28 (Xinhua) -- The issue of third-party online payment permits in China this week will boost the sector's development through giving it a legal status, analysts said.The People's Bank of China (PBOC), or the central bank, on Thursday announced its first batch of electronic payment licenses to 27 qualified third-party online payment platforms, including Alipay, Tenpay and 99bill.It also stipulated that all the third-party payment businesses should obtain licenses before September, or cease doing business.The move has long been awaited after the central bank said in June last year that non-financial institution payment service would be regulated, and that all businesses involved in the service must get licenses before Sept. 1, 2011.The license covers payment transactions such as Internet payment, mobile phone payment, bank card acquiring service, issuance and accept of prepaid cards and currency exchange.The move provides a legal status for the third-party payment sector so that it can develop in a more standard and healthy way, said Zhang Meng, an analyst with Analysys International, an Internet market information provider.Third-party payment enterprises refer to those non-financial operators who work as the third party between buyers and sellers to provide payment settlement through Internet, telephones or mobile phones.China has the world's highest number of Internet users, with about 457 million netizens, among whom 148 million were active online shoppers as of the end of last year.China's online payment topped 1.09 trillion yuan (167.29 billion U.S. dollars) last year. The figure was 397.3 billion yuan in the first quarter this year, almost doubled year-on-year.99bill CEO Guan Guoguang called the issue of the third-party payment licenses "a milestone" for China's e-payment sector.Requiring that enterprises must be licensed to operate e-payment businesses will help standardize the sector, improve services and boost integration of e-payment and e-commerce, said Guan.The first group of e-payment license holders include Alipay.com Co. Ltd, a unit of Alibaba Group Holding which owns the country's largest e-commerce website Alibaba.com Co. Ltd.; China UMS, a unit of China UnionPay Co. Ltd; Tenpay.com, an e-payment platform developed by Chinese Internet giant Tencent Holdings and Shengfutong, launched by Shanda Interactive Entertainment.Five applicants, however, failed to get licenses.Businesses with licenses will attract more investment and high-end personnel, says iResearch analyst Cheng Shanbao.For those without a license, they will be merged or have to pull out of the sector, according to Yeepay CEO Tang Bin.The central bank selected enterprises that have good management and risk control systems, as well as profit prospects, Zhang Meng said.Mergers are inevitable as the cut-off date of Sept. 1 is approaching, he added.The third-party payment enterprises mainly profit from 1 to 4 percent fees, but analysts believe profits from the fees might be reduced due to fierce competition.

来源：资阳报